← Leaderboards
Colleen Volger
University Of Michigan At Ann Arbor
$1,733,669
Attributed
$1,733,669
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $640.1K · FY2014–16$1M$750K$500K$250K$0
'14
'15
'16
Funding mix
By agency
NIH$1,733,669 · 1
By mechanism
N01$1,733,669 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Peter K Henke$8,173,091
- Mark E Meyerhoff$16,191,724
- Thomas William Wakefield$8,538,099
- Max S. Wicha$49,028,071
- David Ginsburg$18,067,006
Others in their field
Top investigators on “Venous”
- David R. Weir · University Of Michigan At Ann Arbor$164,561,836
- Paul M. Ridker · Brigham And Women'S Hospital$57,875,056
- Paul S. Aisen · Cognition Therapeutics, Inc.$39,054,712
- Joel S. Bennett · University Of Pennsylvania$35,473,908
- Robert A Hummer · Univ Of North Carolina Chapel Hill$35,410,813
- Kenneth M Langa · University Of Michigan At Ann Arbor$34,192,762
Research focus
VenousAdultAdverse EffectsBlood VesselsCase StudyCessation Of LifeClinical ResearchContractsDeep Vein ThrombosisDiagnosticDrug KineticsFundingHemorrhageInnovationMedicalModalityVeinsAccountingNational Heart, Lung, And Blood InstitutePhase 1 StudyProduct DevelopmentProgramsPulmonary EmbolismPulmonary Hypertension
Grant awards (3)
IGF::OT::IGF Vascular Interventions/Innovations and Therapeutic Advances(VITA): A Phase 1 Study to Assess the Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects and Calf Vein DVT$640,087
N01 · FY2016 · HL · contact PI
IGF::OT::IGF Vascular Interventions/Innovations and Therapeutic Advances(VITA): A Phase 1 Study to Assess the Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects and Calf Vein DVT$590,391
N01 · FY2015 · HL · contact PI
IGF::OT::IGF Vascular Interventions/Innovations and Therapeutic Advances(VITA): A Phase 1 Study to Assess the Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects and Calf Vein DVT$503,191
N01 · FY2014 · HL · contact PI